Literature DB >> 23767862

Efficacy and tolerability of an herbal formulation for weight management.

Judith S Stern1, Jan Peerson, Artatrana T Mishra, Venkata Sadasiva Rao Mathukumalli, Poorna Rajeswari Konda.   

Abstract

The clinical effects and tolerability of a novel herbal formulation comprising the extracts of Sphaeranthus indicus and Garcinia mangostana were assessed in two similarly designed randomized, double-blind, placebo-controlled, clinical trials in 100 human subjects with a body mass index (BMI) between 30 and 40 kg/m². Participants were randomized into two groups receiving either 400 mg of herbal blend twice daily or two identical placebo capsules. All subjects received three meals (2000 kcal/day) throughout the study and walked 5 days a week for 30 min. The primary outcome was reduction in body weight. Secondary outcomes were reduction in BMI and in waist and hip circumference. Serum glycemic, lipid, and adiponectin levels were also measured. Ninety-five subjects completed the trials, and data from these two studies were pooled and analyzed. At study conclusion (8 weeks), statistically significant reductions in body weight (5.2 kg; P<.0001), BMI (2.2 kg/m²; P<.0001), as well as waist (11.9 cm; P<.0001) and hip circumferences (6.3 cm; P=.0001) were observed in the herbal group compared with placebo. An increase in serum adiponectin concentration was also found in the herbal group versus placebo (P=.0008) at study conclusion along with reductions in fasting blood glucose (12.2%, P=.01), cholesterol (13.8%, P=.002), and triglyceride (41.6%, P<.0001) concentrations. No changes were seen across organ function panels, multiple vital signs, and no major adverse events were reported. The minor adverse events were equally distributed between the two groups. Our findings suggest that the herbal blend appears to be a well-tolerated and effective ingredient for weight management.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23767862      PMCID: PMC3684102          DOI: 10.1089/jmf.2012.0178

Source DB:  PubMed          Journal:  J Med Food        ISSN: 1096-620X            Impact factor:   2.786


  33 in total

1.  The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes.

Authors:  A Bonen; N N Tandon; J F C Glatz; J J F P Luiken; G J F Heigenhauser
Journal:  Int J Obes (Lond)       Date:  2006-06       Impact factor: 5.095

2.  Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans.

Authors:  Norbert Stefan; Barbora Vozarova; Tohru Funahashi; Yuji Matsuzawa; Christian Weyer; Robert S Lindsay; Jack F Youngren; Peter J Havel; Richard E Pratley; Clifton Bogardus; P Antonio Tataranni
Journal:  Diabetes       Date:  2002-06       Impact factor: 9.461

3.  Overweight, obesity, and health-related quality of life among adolescents: the National Longitudinal Study of Adolescent Health.

Authors:  Karen C Swallen; Eric N Reither; Steven A Haas; Ann M Meier
Journal:  Pediatrics       Date:  2005-02       Impact factor: 7.124

4.  Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function.

Authors:  Fitsum Guebre-Egziabher; Jacques Bernhard; Tohru Funahashi; Aoumeur Hadj-Aissa; Denis Fouque
Journal:  Nephrol Dial Transplant       Date:  2004-12-07       Impact factor: 5.992

5.  Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes.

Authors:  T Yamauchi; H Waki; J Kamon; K Murakami; K Motojima; K Komeda; H Miki; N Kubota; Y Terauchi; A Tsuchida; N Tsuboyama-Kasaoka; N Yamauchi; T Ide; W Hori; S Kato; M Fukayama; Y Akanuma; O Ezaki; A Itai; R Nagai; S Kimura; K Tobe; H Kagechika; K Shudo; T Kadowaki
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

6.  Diet-induced adipocyte number increase in adult rats: a new model of obesity.

Authors:  I M Faust; P R Johnson; J S Stern; J Hirsch
Journal:  Am J Physiol       Date:  1978-09

7.  Assessing Impact of Weight on Quality of Life.

Authors:  R L Kolotkin; S Head; M Hamilton; C K Tse
Journal:  Obes Res       Date:  1995-01

8.  Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression.

Authors:  Philip A Kern; Gina B Di Gregorio; Tong Lu; Negah Rassouli; Gouri Ranganathan
Journal:  Diabetes       Date:  2003-07       Impact factor: 9.461

9.  Anti-Obesity Drugs: A Review about Their Effects and Safety.

Authors:  Jun Goo Kang; Cheol-Young Park
Journal:  Diabetes Metab J       Date:  2012-02-17       Impact factor: 5.376

10.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.

Authors:  T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440

View more
  4 in total

1.  Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects.

Authors:  Venkateshwarlu Kudiganti; Raveendra Ramamurthy Kodur; Sushma Raveendra Kodur; Manjunath Halemane; Dheeraj Kumar Deep
Journal:  Lipids Health Dis       Date:  2016-08-24       Impact factor: 3.876

2.  Toxicological studies on the botanical supplement LI12542F6 containing extracts of Sphaeranthus indicus flower heads and Mangifera indica (mango tree) bark.

Authors:  Earle R Nestmann; Venkata Krishnaraju Alluri; Sundararaju Dodda; Barbara A Davis
Journal:  Food Sci Nutr       Date:  2019-01-29       Impact factor: 2.863

Review 3.  Risks Associated with the Use of Garcinia as a Nutritional Complement to Lose Weight.

Authors:  Naroa Andueza; Rosa M Giner; Maria P Portillo
Journal:  Nutrients       Date:  2021-01-29       Impact factor: 5.717

Review 4.  Mangosteen Pericarp and Its Bioactive Xanthones: Potential Therapeutic Value in Alzheimer's Disease, Parkinson's Disease, and Depression with Pharmacokinetic and Safety Profiles.

Authors:  Ha Thi Thu Do; Jungsook Cho
Journal:  Int J Mol Sci       Date:  2020-08-27       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.